1
|
Yang YY, Jun S. The Effects of Cognitive Behavioral Therapy for Insomnia among College Students with Irritable Bowel Syndrome: A Randomized Controlled Trial. Int J Environ Res Public Health 2022; 19:14174. [PMID: 36361052 PMCID: PMC9658882 DOI: 10.3390/ijerph192114174] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/27/2022] [Revised: 10/25/2022] [Accepted: 10/26/2022] [Indexed: 06/16/2023]
Abstract
The aim of the study was to develop and evaluate cognitive behavioral therapy for insomnia (CBT-I) among college students with irritable bowel syndrome (IBS). We randomly assigned 60 college students with IBS comorbid insomnia to the experimental group who received CBT-I for 90 min once a week for 4 weeks and the control (non-CBT-I) group. Participants completed self-report measures of insomnia severity, pre-sleep arousal, sleep-related dysfunctional cognitions, maladaptive sleep habits, IBS symptom severity and IBS quality of life (QOL) at baseline, after intervention, and at 3-month follow-up. Sleep pattern, GI symptoms during sleep and Interleukin-6 (IL-6) and C-Reaction Protein (CRP) were measured at baseline and after intervention. The experimental group showed significant decreases in insomnia severity, sleep onset latency, total time in bed, pre-sleep arousal, GI symptoms during sleep, sleep-related dysfunctional cognitions, maladaptive sleep habits, and IBS symptom severity, compared with the control group. This group also showed significant increases in sleep efficiency and IBS QOL compared with the control group. No significant differences were observed between the levels of IL-6 and CRP of both groups. CBT-I for college students with comorbid IBS and insomnia was effective in reducing insomnia, IBS symptom severity, and IBS QOL.
Collapse
Affiliation(s)
- Yun-Yi Yang
- Department of Nursing, Healthcare Science & Human Ecology, Dong-Eui University, Busan 47340, Korea
| | - Sangeun Jun
- College of Nursing, Keimyung University, Daegu 42601, Korea
| |
Collapse
|
2
|
Jun S, Lee K, Song J. M186 Automated processing of sample preparation for homocysteine analysis using LC-MS/MS. Clin Chim Acta 2022. [DOI: 10.1016/j.cca.2022.04.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
3
|
Kim BS, Kang J, Jun S, Kim H, Pak K, Kim GH, Heo HJ, Kim YH. Association between immunotherapy biomarkers and glucose metabolism from F-18 FDG PET. Eur Rev Med Pharmacol Sci 2020; 24:8288-8295. [PMID: 32894535 DOI: 10.26355/eurrev_202008_22625] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE To assess associations between parameters derived from F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) and mRNA expression levels of immune checkpoint biomarkers such as programmed death receptor 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte antigen 4 (CTLA-4) as well as tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC) patients. PATIENTS AND METHODS Integrated data were downloaded from Genomic Data Common Data Portal. Clinical, mRNA-seq, and whole exome-seq data of lung adenocarcinoma and squamous cell carcinoma from The Cancer Genome Atlas (TCGA) database were analyzed. TMB was defined as the total number of somatic missense mutations per megabase of the genome examined. Expression levels of PD-1, PD-L1, CTLA4 mRNA and TMB were collected. Correlations between imaging parameters of glucose metabolism and the expression levels of genomic biomarkers from cancers were evaluated. Bonferroni correction (adjusted p<0.0027) was applied to reduce type 1 error. RESULTS Of 31 NSCLC cases, 11 cases were adenocarcinoma (LUAD) and 20 were squamous cell carcinoma (LUSC). In linear regression analysis, texture parameters such as low gray-level run emphasis (LGRE, R2=0.48, p<0.0001), short run low gray-level emphasis (SRLGE, R2=0.45, p<0.0001) and long run low gray-level emphasis (LRLGE, R2=0.41, p=0.0001) derived from gray-level run length matrix (GLRLM) showed remarkable correlation with PD-L1 mRNA expression. Expression of PD-1, CTLA-4, and TMB failed to show any significant correlation with parameters of the F-18 FDG PET/CT. CONCLUSIONS Texture parameters derived from PET, known to indicate glucose uptake distribution, were correlated with expression of PD-L1 mRNA but not with expression of PD-1, CTLA-4 and TMB. Thus, tumoral heterogeneity could be a surrogate marker for the identification of PD-L1 level in NSCLC.
Collapse
Affiliation(s)
- B S Kim
- Department of Nuclear Medicine, Kosin University Gospel Hospital, University of Kosin College of Medicine, Busan, Republic of Korea.
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Pizzurro S, Pirzio F, Jun S, Di Lieto A, Tonelli M, Agnesi A. Multi-Watt, mJ nanosecond pulses amplification in a Yb:LuLiF 4 single crystal fiber grown by micro-pulling-down. EPJ Web Conf 2020. [DOI: 10.1051/epjconf/202024305001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
5
|
Qin Y, Cai J, Ji W, Chen X, Tian L, Jun S, Wang L, He X. Intraspinal Paragonimiasis in Children: MRI Findings and Suggestions for Pathogenesis. AJNR Am J Neuroradiol 2019; 40:2166-2171. [PMID: 31727748 DOI: 10.3174/ajnr.a6296] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2019] [Accepted: 09/03/2019] [Indexed: 12/27/2022]
Abstract
BACKGROUND AND PURPOSE Intraspinal paragonimiasis is a rare entity for which imaging findings have seldom been described. The present study investigated the MR imaging features of spinal paragonimiasis, thus providing diagnostic imaging evidence and exploring the possible pathogenesis of intraspinal paragonimiasis. MATERIALS AND METHODS The clinical and imaging findings of spinal paragonimiasis in 6 children were analyzed retrospectively. Spinal MR imaging was performed in all patients, 5 of whom also underwent enhanced MR imaging. The diagnosis was confirmed by enzyme-linked immunosorbent assay in all cases and postoperative pathology in 4 cases. RESULTS All cases manifested as fusiform-shaped or beanlike masses in the extradural space in the thoracic spine. The extradural masses were connected with pleural lesions through the intervertebral foramen. The plain MR imaging scan showed mixed signals with predominant isointensity on T1WI and hyperintensity on T2WI, among which 5 (5/6) masses presented as patchy hemorrhage with hyperintensity on T1WI. On enhanced scans, all masses (5/5) showed heterogeneous marked enhancement, with thickening and enhancement in the adjacent spinal meninges (5/5). Various degrees of spinal cord compression and edema were found in 5 cases (5/6). CONCLUSIONS MR imaging is sensitive for detecting and characterizing spinal paragonimiasis. The MR imaging features of intraspinal granulomas included localization to the extradural space and thoracic segment, connections between intraspinal lesions and pleural lesions through the intervertebral foramen, and hemorrhagic foci within the mass. These findings support an intraspinal mode of paragonimiasis pathogenesis: The Paragonimus larvae migrate from the chest into the extradural space through the intervertebral foramen.
Collapse
Affiliation(s)
- Y Qin
- From the Departments of Radiology (Y.Q., J.C., L.T., S.J., L.W., X.H.)
| | - J Cai
- From the Departments of Radiology (Y.Q., J.C., L.T., S.J., L.W., X.H.)
| | - W Ji
- Neurosurgery (W.J.), Children's Hospital of Chongqing Medical University, Chongqing, China
| | - X Chen
- Outpatient Surgery (X.C.)
| | - L Tian
- From the Departments of Radiology (Y.Q., J.C., L.T., S.J., L.W., X.H.)
| | - S Jun
- From the Departments of Radiology (Y.Q., J.C., L.T., S.J., L.W., X.H.)
| | - L Wang
- From the Departments of Radiology (Y.Q., J.C., L.T., S.J., L.W., X.H.)
| | - X He
- From the Departments of Radiology (Y.Q., J.C., L.T., S.J., L.W., X.H.)
| |
Collapse
|
6
|
Lee K, Kim S, Jun S, Song S, Klopprogge K, Song J. Effect of HB variants on HbA1c assays in Korea. Clin Chim Acta 2019. [DOI: 10.1016/j.cca.2019.03.622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
7
|
Han M, Lee K, Jun S, Song S, Song J. Identification of the hemoglobin variants by ultra-performance liquid chromatography - Tandem mass spectrometry. Clin Chim Acta 2019. [DOI: 10.1016/j.cca.2019.03.136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
8
|
Kim I, Kim H, Chang W, Kim J, Park N, Youn J, Choi S, Jun S, Cho Y, Yoon H, Nam C, Han S, Hur S, Park H. Efficacy and Safety of Idarucizumab for Rapid Reversal from Dabigatran in Patients Undergoing Orthotopic Heart Transplantation. J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.724] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
9
|
Im C, Seo H, Jun S. The effect of number of electrodes in the multi-array tDCS - A computational study. Brain Stimul 2019. [DOI: 10.1016/j.brs.2018.12.437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
10
|
Han CJ, Jarrett ME, Cain KC, Jun S, Heitkemper MM. Association of Fatigue With TPH2 Genetic Polymorphisms in Women With Irritable Bowel Syndrome. Biol Res Nurs 2018; 21:72-79. [PMID: 30309244 DOI: 10.1177/1099800418806055] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Fatigue is the most common extraintestinal symptom in women with irritable bowel syndrome (IBS). Genetic polymorphisms of monoamines are associated with fatigue in many chronic diseases. In this pilot exploratory study, the primary aim was to determine whether genetic polymorphisms of tryptophan hydroxylase ( TPH1/TPH2), serotonin reuptake transporter ( SERT), or catechol-O-methyltransferase ( COMT) are associated with fatigue in women with IBS. Additionally, analysis explored whether these genetic associations with fatigue would be present when controlling for abdominal pain, psychological distress, feeling stressed, and sleepiness during the day. Secondary analysis of two randomized controlled trial baseline data sets in Caucasian women with IBS ( N = 185) was conducted. Participants kept a daily diary with one dimension (i.e., severity) for each of the 26 symptoms, including fatigue, for 28 days prior to randomization. DNA samples were tested for single-nucleotide polymorphisms (SNPs) of TPH1 (four SNPs) /TPH2 (one SNP), SERT (one SNP), and COMT (one SNP). Analysis of covariance was used to examine associations of percentage of diary days with moderate to very severe symptoms with genetic polymorphisms. Only one SNP, TPH2 rs4570625, was significantly associated with fatigue ( p = .005). T-allele (low functional) carriers of TPH2 (i.e., G/T or T/T genotypes) reported a greater percentage of days with moderate to very severe fatigue than G/G homozygotes ( p = .001). Reduced synthesis of tryptophan in the central nervous system may contribute to reports of fatigue in women with IBS. Understanding genetic risk factors for fatigue may elucidate preemptive strategies to reduce fatigue in individuals with IBS.
Collapse
Affiliation(s)
- Claire J Han
- 1 Department of Public Health, University of Washington & Fred Hutchinson Cancer Research Center, Biobehavioral Cancer Prevention and Control Training Program, Seattle, WA
| | - Monica E Jarrett
- 2 Department of Biobehavioral Nursing and Health Informatics, University of Washington, Seattle, WA, USA
| | - Kevin C Cain
- 3 Department of Biostatistics and Office of Nursing Research, University of Washington, Seattle, WA, USA
| | - Sangeun Jun
- 4 College of Nursing, Keimyung University, Daegu, South Korea
| | - Margaret M Heitkemper
- 2 Department of Biobehavioral Nursing and Health Informatics, University of Washington, Seattle, WA, USA
| |
Collapse
|
11
|
Kim J, Lee H, Lee J, Jun S, Gong H, Chung Y, Kim J, Kim J. Development of New Acupotomy Device Based on Acupotomy Clinical Trials. J Acupunct Meridian Stud 2018. [DOI: 10.1016/j.jams.2018.08.191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
12
|
Jun S, Dr J. Modified Hand Elevation Test as an aid in diagnosing carpal tunnel syndrome. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
13
|
Jun S. SCREENING, BRIEF INTERVENTION, AND REFERRAL TO TREATMENT (SBIRT) FOR ADOLESCENT ALCOHOL USE IN EMERGENCY DEPARTMENTS: A NATIONAL SURVEY OF PEDIATRIC EMERGENCY PHYSICIANS. Paediatr Child Health 2017. [DOI: 10.1093/pch/pxx086.102] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
14
|
Jun S, Yoon J. Litorivivens aequoris sp. nov., a gammaproteobacterium isolated from seawater. Arch Microbiol 2016; 199:591-596. [PMID: 28032190 DOI: 10.1007/s00203-016-1329-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2016] [Revised: 11/21/2016] [Accepted: 12/16/2016] [Indexed: 10/20/2022]
Abstract
A Gram-stain-negative, strictly aerobic, beige-pigmented, motile, chemoheterotrophic, rod-shaped or ovoid bacterium, designated strain KMU-37T, was isolated from seawater at Najeong Beach in the Republic of Korea. Phylogenetic analysis based on the 16S rRNA gene sequence revealed that the novel isolate was affiliated with the genus Litorivivens, class Gammaproteobacteria, showing highest sequence similarity (97.4%) to Litorivivens lipolytica HJTF-7T. The DNA-DNA relatedness values between strains KMU-37T and L. lipolytica HJTF-7T were 11.5 ± 0.4%. The DNA G+C content of strain KMU-37T was determined to be 53.8 mol%. Ubiquinone 8 (Q-8) was the sole respiratory quinone. The predominant cellular fatty acids were C17:1 ω8c and C16:1 ω7c and/or C16:1 ω6c. Strain KMU-37T had phosphatidylethanolamine, phosphatidylglycerol and an unidentified lipid as polar lipids. From the distinct phylogenetic position and combination of genotypic and phenotypic characteristics, the strain is considered to represent a novel species of the genus Litorivivens for which the name Litorivivens aequoris sp. nov. is proposed. The type strain of L. aequoris sp. nov. is KMU-37T (= KCCM 90262T = NBRC 111904T).
Collapse
Affiliation(s)
- Sangeun Jun
- College of Nursing, Keimyung University, 1095 Dalgubeoldaero, Dalseo-Gu, Daegu, 42601, Republic of Korea
| | - Jaewoo Yoon
- College of Pharmacy, Keimyung University, 1095 Dalgubeoldaero, Dalseo-Gu, Daegu, 42601, Republic of Korea.
| |
Collapse
|
15
|
Takenami T, Maeda S, Karasawa H, Mochizuki Y, Aizawa T, Jun S, Musha H, Morikawa T, Nakagawa K, Hayashi H, Motoi F, Naitoh T, Unno M. 46P Identification of novel biomarkers distinguishing pancreatic head cancer from distal cholangiocarcinoma discovered by proteomics analysis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw574.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Jun S, Karasawa H, Suzuki T, Nakayama S, Katagiri M, Maeda S, Ohnuma S, Motoi F, Naitoh T, Unno M. 34P The expression and functional role of Cripto-1 in human colorectal cancer. Ann Oncol 2016. [DOI: 10.1016/s0923-7534(21)00194-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
17
|
Jun S, Karasawa H, Suzuki T, Nakayama S, Katagiri M, Maeda S, Ohnuma S, Motoi F, Naitoh T, Unno M. 34P The expression and functional role of Cripto-1 in human colorectal cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw574.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Sarkar S, Jun S, Rellick S, Quintana DD, Cavendish JZ, Simpkins JW. Expression of microRNA-34a in Alzheimer's disease brain targets genes linked to synaptic plasticity, energy metabolism, and resting state network activity. Brain Res 2016; 1646:139-151. [PMID: 27235866 DOI: 10.1016/j.brainres.2016.05.026] [Citation(s) in RCA: 119] [Impact Index Per Article: 14.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2016] [Revised: 05/06/2016] [Accepted: 05/13/2016] [Indexed: 01/07/2023]
Abstract
Polygenetic risk factors and reduced expression of many genes in late-onset Alzheimer's disease (AD) impedes identification of a target(s) for disease-modifying therapies. We identified a single microRNA, miR-34a that is over expressed in specific brain regions of AD patients as well as in the 3xTg-AD mouse model. Specifically, increased miR-34a expression in the temporal cortex region compared to age matched healthy control correlates with severity of AD pathology. miR-34a over expression in patient's tissue and forced expression in primary neuronal culture correlates with concurrent repression of its target genes involved in synaptic plasticity, oxidative phosphorylation and glycolysis. The repression of oxidative phosphorylation and glycolysis related proteins correlates with reduced ATP production and glycolytic capacity, respectively. We also found that miR-34a overexpressed neurons secrete miR-34a containing exosomes that are taken up by neighboring neurons. Furthermore, miR-34a targets dozens of genes whose expressions are known to be correlated with synchronous activity in resting state functional networks. Our analysis of human genomic sequences from the tentative promoter of miR-34a gene shows the presence of NFκB, STAT1, c-Fos, CREB and p53 response elements. Together, our results raise the possibilities that pathophysiology-induced activation of specific transcription factor may lead to increased expression of miR-34a gene and miR-34a mediated concurrent repression of its target genes in neural networks may result in dysfunction of synaptic plasticity, energy metabolism, and resting state network activity. Thus, our results provide insights into polygenetic AD mechanisms and disclose miR-34a as a potential therapeutic target for AD.
Collapse
Affiliation(s)
- S Sarkar
- Center for Basic and Translational Stroke Research, Department of Physiology and Pharmacology, West Virginia University, Morgantown, WV 26506, United States
| | - S Jun
- Center for Basic and Translational Stroke Research, Department of Physiology and Pharmacology, West Virginia University, Morgantown, WV 26506, United States
| | - S Rellick
- Center for Basic and Translational Stroke Research, Department of Physiology and Pharmacology, West Virginia University, Morgantown, WV 26506, United States
| | - D D Quintana
- Center for Basic and Translational Stroke Research, Department of Physiology and Pharmacology, West Virginia University, Morgantown, WV 26506, United States
| | - J Z Cavendish
- Center for Basic and Translational Stroke Research, Department of Physiology and Pharmacology, West Virginia University, Morgantown, WV 26506, United States
| | - J W Simpkins
- Center for Basic and Translational Stroke Research, Department of Physiology and Pharmacology, West Virginia University, Morgantown, WV 26506, United States.
| |
Collapse
|
19
|
Jun S, Kim H, Nam HY. A new method for segmentation of FDG PET metabolic tumour volume using the peritumoural halo layer and a 10-step colour scale. A study in patients with papillary thyroid carcinoma. Nuklearmedizin 2015; 54:272-85. [PMID: 26429587 DOI: 10.3413/nukmed-0749-15-06] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2015] [Accepted: 09/22/2015] [Indexed: 12/15/2022]
Abstract
AIM We observed a layer between tumour activity and background on FDG PET/CT with the 10-step colour scale and the window level set properly. We named the layer peritumoral halo layer (PHL). We performed this study to establish the reliability of metabolic tumor volume (MTV) segmentation using PHL (MTV(PHL)) in patients with papillary thyroid carcinoma. PATIENTS, METHODS Of a total of 140 papillary thyroid carcinoma (PTC) patients, 70 (50.0%) had FDG-avid PTC. In these patients, MTV(PHL), MTV segmented according to fixed 50% SUVmax (MTV(50%)), and fixed SUV with 2.5 to 4.0 (MTV(2.5) to MTV(4.0)) were compared with pathologic tumour volume (PTV). The absolute percentage difference between MTV(PHL) and PTV was compared in micropapillary carcinoma (MPTC) and non-micropapillary carcinoma (non-MPTC) subgroups. The % SUVmax and SUV thresholds of MTV(PHL) were compared with tumour SUVmax. RESULTS Among the MTVs, MTV(50%) was not correlated with PTV (r = -0.16, p = 0.182) and was not reliable according to the Bland-Altman plot. Although MTV(2.5), MTV(3.0), MTV(3.5), and MTV(4.0) correlated with PTV (r = 0.85, 0.86, 0.87, and 0.87, respectively; p < 0.001), these MTVs were not reliable on Bland-Altman analyses. MTV(PHL) was significantly correlated with PTV (r = 0.80, p < 0.001), and the Bland-Altman plot did not show systemic error. The MTV(PHL) was more accurate in non-MPTC than in MPTC (p < 0.001), and the absolute % difference was smaller as PTV became larger (σ = -0.65, p < 0.001). The MTV(PHL) thresholds had correlations with SUVmax (% SUVmax threshold: σ = -0.87, p < 0.001; SUV threshold: r = 0.88, p < 0.001). CONCLUSIONS MTV(PHL) was more reliable than MTV(%SUVmax) or MTV(SUV). The reliability of MTV(PHL) improved with larger PTVs. The threshold of the MTV(PHL) was naturally altered by PHL according to SUVmax.
Collapse
Affiliation(s)
| | | | - H-Y Nam
- Hyun-Yeol Nam, M.D., Samsung Changwon Hospital, 158, Paryong-ro, Masan Hoewon-gu, Changwon-si, Korea, 630-723, Tel. +82/55/290-65 93; Fax -55 98,
| |
Collapse
|
20
|
Qianqian Y, Yong Y, Zhaodong C, Yonghui T, Jun S, Yuzheng H. Differential Protein Expression between Type 1 Diabetic Cataract and Age-Related Cataract Patients. Folia Biol (Praha) 2015; 61:74-80. [PMID: 26333124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Diabetes has become one of the major diseases affecting human health. Diabetic cataracts (DCs) are considered a common complication in diabetic patients. The present study investigated differences in lens proteomic profiles between DCs and age-related cataracts (ACs) to determine the mechanism underlying the formation of DCs. Intrasurgical samples were collected from eight DC patients and 12 AC patients, and lens proteins were extracted by lysis and separated using two-dimensional gel electrophoresis (2-DE). The electrophoretic bands were analysed using PD-Quest software 8.0.1. Differentially expressed proteins were identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS) and peptide mass fingerprinting combined with protein database searching. In the 2-DE maps, the DC and AC lens proteins migrated in the region of pH 5-9 with a relative molecular weight (RMW) of 14-97 kDa, whereas the RMW of more abundant crystallin was 20-31 kDa. Approximately three protein spots with differential intensity were detected. Two crystallin proteins (αB and βB1) were identified using MALDI-TOF-MS. Proteomic analysis of the crystalline humour is feasible, and the proteins can be well separated; moreover, differentially expressed lens proteins can be analysed using 2-DE and mass spectrometry to compare DC and AC. The present results indicate that the αB and βB1 crystallins may accelerate the development of DCs. These techniques offer new avenues for mechanistic evaluation and future prevention or therapy of DCs.
Collapse
Affiliation(s)
- Y Qianqian
- Department of Ophthalmology, Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China
| | - Y Yong
- Department of Ophthalmology, Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China
| | - C Zhaodong
- Department of Ophthalmology, Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China
| | - T Yonghui
- The Key Lab of Technology on Parasitic Diseases Prevent and Control, Ministry of Health; Jiangsu Institute of Parasitic Diseases, Wuxi, China
| | - S Jun
- Department of Ophthalmology, Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China
| | - H Yuzheng
- The Key Lab of Technology on Parasitic Diseases Prevent and Control, Ministry of Health; Jiangsu Institute of Parasitic Diseases, Wuxi, China
| |
Collapse
|
21
|
Choi Y, Ju S, Chae SH, Jun S, Park SM, Lee S, Lee HW, Ji CH. Low Frequency Vibration Energy Harvester Using Spherical Permanent Magnet with Non-uniform Mass Distribution. ACTA ACUST UNITED AC 2013. [DOI: 10.1088/1742-6596/476/1/012123] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
22
|
Chae SH, Ju S, Choi Y, Jun S, Park SM, Lee S, Lee HW, Ji CH. Electromagnetic Vibration Energy Harvester Using Springless Proof Mass and Ferrofluid as a Lubricant. ACTA ACUST UNITED AC 2013. [DOI: 10.1088/1742-6596/476/1/012013] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
23
|
Wei Z, Jun S, Hui Z, Quan X, Liu B. NMR metabonomics analysis of helicopter aviators in maritime. ARCH MAL PROF ENVIRO 2013. [DOI: 10.1016/j.admp.2013.07.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
24
|
Choi W, Jun S, Nguyen L, Rungraeng N, Yi H, Balasubramanian S, Puri V, Lee J. 3-D Milk Fouling Modeling of Plate Heat Exchangers with Different Surface Finishes Using Computational Fluid Dynamics Codes. J FOOD PROCESS ENG 2012. [DOI: 10.1111/j.1745-4530.2012.00684.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
25
|
Abstract
A theoretical model of foam as a consolidating continuum is proposed. The general model is applied to foam in a gravity settler. It is predicted that liquid drainage from foam in a gravity settler begins with a slow drainage stage. Next, a stage with faster drainage occurs where the drainage rate doubles compared to the initial stage. The experiments conducted within the framework of this work confirmed the theoretical predictions and allowed measurements of foam characteristics. Foams of three different concentrations of Pantene Pro-V Classic Care Solutions shampoo were studied, as well as the addition of polyethylene oxide (PEO) in one case. The shampoo's main foaming components are sodium lauryl sulfate and sodium laureth sulfate. It is shown to what extent foam drainage is slowed down by using higher shampoo concentrations and how it is further decreased by adding polymer (PEO).
Collapse
Affiliation(s)
- S Jun
- Department of Mechanical and Industrial Engineering, University of Illinois at Chicago, 842 West Taylor Street, Chicago, Illinois 60607-7022, USA
| | | | | |
Collapse
|
26
|
Lipton A, Fizazi K, Stopeck A, Henry D, Brown J, Saad F, Yardley D, Maroto P, Ke C, Jun S. 3061 POSTER Prevention of Skeletal-Related Events With Denosumab or Zoledronic Acid – Combined Analysis From 3 Registrational Trials. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71134-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
27
|
Vadhan-Raj S, Henry DH, von Moos R, Hungria V, Goldwasser F, Scagliotti G, Wang J, Jun S, Dansey RD, Yeh H. Denosumab in the treatment of bone metastases from advanced cancer or multiple myeloma (MM): Analyses from a phase III randomized trial. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9042] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Lipton A, Stopeck A, von Moos R, Henry DH, Richardson GE, Rodriguez GI, Bourgeois HP, Ke C, Jun S, Dansey RD. A meta-analysis of results from two randomized, double-blind studies of denosumab versus zoledronic acid (ZA) for treatment of bone metastases. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Henry DH, von Moos R, Hungria V, Costa L, Woll PJ, Scagliotti G, Wang J, Jun S, Dansey RD, Yeh H. Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advanced cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9133] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Henry D, von Moos R, Vadhan-Raj S, Hungria V, Spencer A, Hirsh V, Wang J, Jun S, Yeh H, Dansey R. 20LBA A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)72055-5] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
31
|
Smith MR, Ellis G, Saad F, Tammela T, Bone H, Egerdie B, Ke C, Jun S, Dansey R, Goessl C. Effect of denosumab on bone mineral density (BMD) in women with breast cancer (BC) and men with prostate cancer (PC) undergoing hormone ablation therapy. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9520] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9520 Background: Hormone ablation therapies, including adjuvant aromatase inhibitor (AI) therapy and androgen deprivation therapy (ADT), improve recurrence-free survival in patients (pts) with BC and PC, respectively. However, these treatments increase bone resorption, leading to bone loss and fractures. RANKL is a key mediator of osteoclast-mediated bone resorption. In this 24 month (mo) comparison, we investigated the effects of denosumab, a fully human monoclonal antibody against RANKL, on preserving BMD across both populations. Methods: Two trials were conducted: a 24-mo BC study and a 36-mo PC study. Postmenopausal women with low BMD receiving AI therapy for nonmetastatic BC and men receiving ADT for nonmetastatic PC (with low BMD or history of osteoporotic fracture if < 70 yrs) were randomized to receive placebo or denosumab 60mg subcutaneously every 6 mos. All pts in both studies were prescribed calcium and vitamin D supplements. The primary endpoint was % change from baseline in lumbar spine (LS) BMD at 12 mos for the BC study and at 24 mos for the PC study. Herein, we present changes in BMD at 24 mos at LS, total hip (TH), and 1/3 radius from both studies. Power calculations were based on enrollment of at least 208 patients in the BC study (for primary endpoint only) and 1226 in the PC study (for primary and key secondary endpoints). The actual numbers randomized were 252 and 1468, respectively. Results: Denosumab increased BMD of the LS, TH, and 1/3 radius compared with placebo at 24 mos in both pt populations ( Table ). In both studies, differences between denosumab and placebo at each skeletal site were consistent, and the effects of denosumab were statistically significantly different from placebo as early as 1 month at the LS in both studies. The overall safety profile was similar to placebo in each study. Conclusions: Denosumab consistently increased BMD at all 3 skeletal sites compared with placebo in both women with BC undergoing AI therapy and in men with PC undergoing ADT. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- M. R. Smith
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - G. Ellis
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - F. Saad
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - T. Tammela
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - H. Bone
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - B. Egerdie
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - C. Ke
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - S. Jun
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - R. Dansey
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| | - C. Goessl
- Massachusetts General Hospital Cancer Center, Boston, MA; Seattle Cancer Care Alliance, Seattle, WA; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; Tampere University Hospital, Tampere, Finland; Michigan Bone and Mineral Clinic, Detroit, MI; Urology Associates Urologic Medical Research, Kitchener, ON, Canada; Amgen, Inc., Thousand Oaks, CA
| |
Collapse
|
32
|
Chae Y, Kim J, Sohn S, Kim S, Lee S, Moon J, Jeon S, Cho Y, Choi G, Jun S. RIPK1 gene polymorphism as a prognostic marker for survival in patients with colorectal cancer. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e15078] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e15078 Background: Since apoptosis plays a key role in cancer progression, we hypothesized that single nucleotide polymorphisms (SNPs) of apoptosis-related gene can affect survival after curative resection in patients with colorectal cancer. Patients and Methods: Three hundred and ninety seven patients with colorectal cancer who underwent surgery with curative intent were enrolled in the present study. The genomic DNA was extracted from fresh colorectal mucosal tissue, and the 19 SNPs of 15 apoptosis-related genes (CASP3, CASP6–10, FAS, FAS ligand [FASLG], TNSFR1A, TNSFR10B, RIPK1, BCL2, BCL2 ligand [BCL2L], TP53, and PTGS2) were determined using a PCR-RFLP assay. Results: The median age of the patients was 63 years (range, 21–85), and 218 (54.9%) patients had colon cancer and 179 (45.1%) patients rectal cancer. Pathologic stages after surgery were as follows: stage 0/I (n=86, 21.7%), stage II (n=146, 36.8%), stage III (n=145, 36.5%), and stage IV (n=20, 5.0%). Multivariate survival analysis including pathologic stage, differentiation, age, and CEA level showed that relapse-free survival for the patients with the GA+AA genotype of RIPK1 (Receptor interacting serine/threonine kinase 1) +83G>A (rs2272990) was worse than for the patients with the GG genotype (hazard ratio [HR]=1.66, 95% confidence interval [CI]=1.03–2.68, p=0.038). However, no associations were observed between the polymorphisms and overall survival (OS) in a multivariate analysis. Conclusions: RIPK1 gene polymorphism can be considered as a possible prognostic marker for survival after curative resection in patient with colorectal cancer. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- Y. Chae
- Kyungpook National University Hospital, Daegu, Republic of Korea; Dongguk University Kyeongju Hospital, KyeongJu, Republic of Korea
| | - J. Kim
- Kyungpook National University Hospital, Daegu, Republic of Korea; Dongguk University Kyeongju Hospital, KyeongJu, Republic of Korea
| | - S. Sohn
- Kyungpook National University Hospital, Daegu, Republic of Korea; Dongguk University Kyeongju Hospital, KyeongJu, Republic of Korea
| | - S. Kim
- Kyungpook National University Hospital, Daegu, Republic of Korea; Dongguk University Kyeongju Hospital, KyeongJu, Republic of Korea
| | - S. Lee
- Kyungpook National University Hospital, Daegu, Republic of Korea; Dongguk University Kyeongju Hospital, KyeongJu, Republic of Korea
| | - J. Moon
- Kyungpook National University Hospital, Daegu, Republic of Korea; Dongguk University Kyeongju Hospital, KyeongJu, Republic of Korea
| | - S. Jeon
- Kyungpook National University Hospital, Daegu, Republic of Korea; Dongguk University Kyeongju Hospital, KyeongJu, Republic of Korea
| | - Y. Cho
- Kyungpook National University Hospital, Daegu, Republic of Korea; Dongguk University Kyeongju Hospital, KyeongJu, Republic of Korea
| | - G. Choi
- Kyungpook National University Hospital, Daegu, Republic of Korea; Dongguk University Kyeongju Hospital, KyeongJu, Republic of Korea
| | - S. Jun
- Kyungpook National University Hospital, Daegu, Republic of Korea; Dongguk University Kyeongju Hospital, KyeongJu, Republic of Korea
| |
Collapse
|
33
|
Thomas DM, Chawla S, Skubitz K, Staddon A, Henshaw R, Blay J, Smith J, Ye Z, Roudier M, Jun S. Denosumab for the treatment of giant cell tumor (GCT) of bone: Final results from a proof-of-concept, phase II study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.10510] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10510 Background: GCT of bone is a primary osteolytic bone tumor with low metastatic potential that is associated with significant skeletal morbidity. GCT is rich in stromal cells that express RANKL, a key mediator of osteoclast activation. In this open-label, study, we investigated whether denosumab, a fully human monoclonal antibody against RANKL, could have a potential therapeutic effect on giant cell histology for patients with GCT. Methods: In this single-arm study, 37 patients with measurable or unresectable GCT received denosumab 120 mg subcutaneously once monthly with loading doses on days 8 and 15 of month 1. The primary endpoint was the proportion of patients with a tumor response (≥90% elimination of giant cells or no radiographic progression of the target lesion) at week 25 as assessed by histology and CT or MRI. A sample size of 35 patients was planned. All 37 enrolled patients were evaluated for safety; 35 were eligible for efficacy evaluation (2 had insufficient histology or radiology data). Results: Thirty of 35 patients (86%; 95% CI 70%-95%) had a tumor response: 20 of 20 by histology and 10 of 15 by radiology. Of 31 patients with data for assessments of clinical benefit, 26 (84%%; 95% CI 66%-95%) reported reduced pain or improvement in functional status. Bone repair was reported in 9 patients (29%; 95% CI 14%-48%). Suppression of the bone turnover markers urinary N-telopeptide and serum C-telopeptide was seen as early as 28 days after the first dose and sustained for the duration of the study. Adverse events (AEs) were reported in 33 patients (89%). One death due to surgical complications (not treatment-related) occurred on-study. No patient experienced treatment-related serious AEs or developed anti-denosumab antibodies. Conclusions: In this study, 86% of patients with measurable or unresectable GCT experienced a tumor response with denosumab. Further clinical trials of denosumab as a new therapy for GCT are warranted. [Table: see text]
Collapse
Affiliation(s)
- D. M. Thomas
- Peter MacCallum Cancer Centre, Melbourne, Australia; Sarcoma Oncology Center, Santa Monica, CA; University of Minnesota, Minneapolis, MN; Pennsylvania Hematology and Oncology Association, Philadelphia, PA; Washington Cancer Institute, Georgetown University, Washington, DC; Hôpital Edouard Heriot, Lyon, France; Amgen, Inc., Thousand Oaks, CA; Amgen, Inc., Seattle, WA
| | - S. Chawla
- Peter MacCallum Cancer Centre, Melbourne, Australia; Sarcoma Oncology Center, Santa Monica, CA; University of Minnesota, Minneapolis, MN; Pennsylvania Hematology and Oncology Association, Philadelphia, PA; Washington Cancer Institute, Georgetown University, Washington, DC; Hôpital Edouard Heriot, Lyon, France; Amgen, Inc., Thousand Oaks, CA; Amgen, Inc., Seattle, WA
| | - K. Skubitz
- Peter MacCallum Cancer Centre, Melbourne, Australia; Sarcoma Oncology Center, Santa Monica, CA; University of Minnesota, Minneapolis, MN; Pennsylvania Hematology and Oncology Association, Philadelphia, PA; Washington Cancer Institute, Georgetown University, Washington, DC; Hôpital Edouard Heriot, Lyon, France; Amgen, Inc., Thousand Oaks, CA; Amgen, Inc., Seattle, WA
| | - A. Staddon
- Peter MacCallum Cancer Centre, Melbourne, Australia; Sarcoma Oncology Center, Santa Monica, CA; University of Minnesota, Minneapolis, MN; Pennsylvania Hematology and Oncology Association, Philadelphia, PA; Washington Cancer Institute, Georgetown University, Washington, DC; Hôpital Edouard Heriot, Lyon, France; Amgen, Inc., Thousand Oaks, CA; Amgen, Inc., Seattle, WA
| | - R. Henshaw
- Peter MacCallum Cancer Centre, Melbourne, Australia; Sarcoma Oncology Center, Santa Monica, CA; University of Minnesota, Minneapolis, MN; Pennsylvania Hematology and Oncology Association, Philadelphia, PA; Washington Cancer Institute, Georgetown University, Washington, DC; Hôpital Edouard Heriot, Lyon, France; Amgen, Inc., Thousand Oaks, CA; Amgen, Inc., Seattle, WA
| | - J. Blay
- Peter MacCallum Cancer Centre, Melbourne, Australia; Sarcoma Oncology Center, Santa Monica, CA; University of Minnesota, Minneapolis, MN; Pennsylvania Hematology and Oncology Association, Philadelphia, PA; Washington Cancer Institute, Georgetown University, Washington, DC; Hôpital Edouard Heriot, Lyon, France; Amgen, Inc., Thousand Oaks, CA; Amgen, Inc., Seattle, WA
| | - J. Smith
- Peter MacCallum Cancer Centre, Melbourne, Australia; Sarcoma Oncology Center, Santa Monica, CA; University of Minnesota, Minneapolis, MN; Pennsylvania Hematology and Oncology Association, Philadelphia, PA; Washington Cancer Institute, Georgetown University, Washington, DC; Hôpital Edouard Heriot, Lyon, France; Amgen, Inc., Thousand Oaks, CA; Amgen, Inc., Seattle, WA
| | - Z. Ye
- Peter MacCallum Cancer Centre, Melbourne, Australia; Sarcoma Oncology Center, Santa Monica, CA; University of Minnesota, Minneapolis, MN; Pennsylvania Hematology and Oncology Association, Philadelphia, PA; Washington Cancer Institute, Georgetown University, Washington, DC; Hôpital Edouard Heriot, Lyon, France; Amgen, Inc., Thousand Oaks, CA; Amgen, Inc., Seattle, WA
| | - M. Roudier
- Peter MacCallum Cancer Centre, Melbourne, Australia; Sarcoma Oncology Center, Santa Monica, CA; University of Minnesota, Minneapolis, MN; Pennsylvania Hematology and Oncology Association, Philadelphia, PA; Washington Cancer Institute, Georgetown University, Washington, DC; Hôpital Edouard Heriot, Lyon, France; Amgen, Inc., Thousand Oaks, CA; Amgen, Inc., Seattle, WA
| | - S. Jun
- Peter MacCallum Cancer Centre, Melbourne, Australia; Sarcoma Oncology Center, Santa Monica, CA; University of Minnesota, Minneapolis, MN; Pennsylvania Hematology and Oncology Association, Philadelphia, PA; Washington Cancer Institute, Georgetown University, Washington, DC; Hôpital Edouard Heriot, Lyon, France; Amgen, Inc., Thousand Oaks, CA; Amgen, Inc., Seattle, WA
| |
Collapse
|
34
|
Gralow J, Lipton A, Fizazi K, Gao G, Jun S, Yeh H. Effects of denosumab treatment in breast cancer patients with bone metastases and elevated bone resorption levels after therapy with intravenous bisphosphonates: results of a phase 2 randomized trial. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-1155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Abstract #1155
Background: Patients with breast cancer-induced bone disease and elevated urine-N-telopeptide (uNTx), a marker of bone resorption, are at increased risk for skeletal complications, disease progression, and death. Receptor activator of NF-kB ligand (RANKL) mediates osteoclastic bone resorption. Denosumab, a fully human monoclonal antibody, inhibits bone destruction by binding and neutralizing RANKL. Denosumab efficacy and safety were assessed in a phase 2, randomized, open-label, active-controlled trial in patients with bone metastases and elevated levels of uNTx after at least 8 weeks of intravenous (IV) bisphosphonate (BP) therapy. We report results in a subset of patients with breast cancer.
 Methods: Cancer patients with bone metastases and uNTx >50 nM/mM creatinine [Cr] following at least 8 weeks of IV BP therapy were randomized to continue IV BP therapy every 4 weeks (Q4W) or switch to subcutaneous (SC) denosumab injection (180 mg) Q4W or every 12 weeks (Q12W). The primary endpoint was the proportion of patients who achieved uNTx <50 nM/mM at week 13. Safety was also assessed.
 Results: The study population (N = 111) included 46 patients (41%) with breast cancer; the median time since diagnosis of bone metastases was approximately 1 year in both groups. At week 13, 76% of denosumab-treated patients and 33% of IV BP-treated patients had uNTx < 50 nM/mM. Denosumab-induced suppression of uNTx was rapid (as early as 2 weeks after initial treatment), sustained through week 25, and unaffected by baseline uNTx (Table). In the total study population, adverse events of grade 3, 4, or 5 were reported in 25 (71%) IV BP-treated patients and 40 (55%) denosumab-treated patients.
 
 Discussion: Denosumab reduced bone turnover in breast cancer patients with bone metastases and elevated uNTx despite prior IV BP therapy. Phase 3 trials of denosumab in cancer patients with bone metastases are in progress.
Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1155.
Collapse
Affiliation(s)
- J Gralow
- 1 School of Medicine, U of Washington, Seattle, WA
| | - A Lipton
- 2 College of Medicine, Penn State Milton S. Hershey Medical Center, Hershey, PA
| | - K Fizazi
- 3 Dept of Medicine, Institut Gustave Roussy, Villejuif, France
| | - G Gao
- 4 Biostatistics, Amgen Inc., San Francisco, CA
| | - S Jun
- 5 Clinical Development, Amgen Inc., Thousand Oaks, CA
| | - H Yeh
- 5 Clinical Development, Amgen Inc., Thousand Oaks, CA
| |
Collapse
|
35
|
Shim J, Cho I, Khurana H, Li Q, Jun S. Attenuated Total Reflectance–Fourier Transform Infrared Spectroscopy Coupled with Multivariate Analysis for Measurement of Acesulfame-K in Diet Foods. J Food Sci 2008; 73:C426-31. [DOI: 10.1111/j.1750-3841.2008.00751.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
36
|
Ellis GK, Bone HG, Chlebowski RT, Paul D, Spadafora S, Smith J, Fan M, Jun S. Subgroup analysis of a randomized, phase III study of the effect of denosumab in women with nonmetastatic breast cancer receiving aromatase inhibitor (AI) therapy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
37
|
Fizazi K, Lipton A, Mariette X, Suarez T, Body J, Rahim Y, Gralow JR, Gao G, Wu L, Jun S. Denosumab in patients with bone metastases from prostate, breast, and other cancers and elevated urinary N-telopeptide (uNTx) during intravenous bisphosphonate (IV BP) therapy: Final results of a randomized, phase II study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.3596] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
38
|
Thomas D, Chawla SP, Skubitz K, Staddon AP, Henshaw R, Blay JY, Smith J, Ye Z, Roudier M, Jun S. Denosumab treatment of giant cell tumor of bone: Interim analysis of an open-label phase II study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.10500] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
39
|
Chae Y, Kim J, Sohn S, Moon J, Kim S, Ryoo H, Bae S, Choi G, Jun S, Lee M. Prognostic impact of apoptosis-related and DNA repair gene polymorphisms in patients with advanced colorectal cancer treated with capecitabine and oxaliplatin chemotherapy. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
40
|
Lage M, Harrison DJ, Barber B, Jun S. Burden of hospitalizations associated with skeletal related events in patients with breast cancer or lung cancer and bone metastases or multiple myeloma. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.17083] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
17083 Background: Patients with bone metastases secondary to cancer often experience skeletal related events (SREs) including pathological fracture, spinal cord compression, hypercalcemia, bone surgery or radiotherapy, or initiation of opioid analgesic use. These SREs result in major morbidity and reduced quality of life. This research examines hospitalizations associated with SREs. Methods: Data for this study were obtained from i3 LabRx Database (05/01/2000 to 03/31/2005). Individuals were included in the analyses if they had at least two diagnoses of breast cancer (based upon an ICD-9 code of 174.xx), lung cancer (162.xx), or multiple myeloma (203.0x) and had at least two diagnoses of bone metastases (198.5x) after the first diagnosis of cancer. In addition, individuals were required to have at least one SRE (based upon a previously published algorithm) on or after their initial diagnosis of bone metastases (their index date). Individuals were required to be continuously insured for at least 6 months prior to, and at least one month post their index date. Data were analyzed until 03/31/2005 or until the end of their continuous coverage, whichever occurred first. Descriptive statistics for each of these cohorts are provided. Results: A total of 1,204 individuals with breast cancer, 1,094 with lung cancer, and 258 with multiple myeloma were included in the study. The vast majority of individuals with breast cancer (96.5%), lung cancer (95.9%), or multiple myeloma (96.8%) were hospitalized. All three patient groups were likely to have SRE-related hospitalizations; multiple myeloma 43.4%, breast cancer 36.2% and lung cancer 35.6%. The average number of days per patient year that patients were hospitalized related to a diagnosis or procedure for a SRE was 6.75 days for patients with lung cancer, 6.56 days for patients with multiple myeloma, and 3.75 days for patients with breast cancer. Conclusion: Hospitalizations related to SREs are common and the number of days per year is substantial. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Lage
- HealthMetrics Outcomes Research, Groton, CT; Amgen, Thousand Oaks, CA
| | - D. J. Harrison
- HealthMetrics Outcomes Research, Groton, CT; Amgen, Thousand Oaks, CA
| | - B. Barber
- HealthMetrics Outcomes Research, Groton, CT; Amgen, Thousand Oaks, CA
| | - S. Jun
- HealthMetrics Outcomes Research, Groton, CT; Amgen, Thousand Oaks, CA
| |
Collapse
|
41
|
Cho Y, Chae Y, Kim J, Shon S, Moon J, Jeon S, Park J, Lee I, Lee I, Choi G, Jun S. Vascular endothelial growth factor gene polymorphisms and risk of colorectal cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.4123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4123 Background: Angiogenesis is closely related to the development, growth, and metastasis of solid tumors, including colorectal cancer (CRC), and the vascular endothelial growth factor (VEGF) is known to be a potent pro-angiogenic factor. Accordingly, the present study was conducted to evaluate the potential association between two VEGF polymorphisms (+405G > C, and 936C > T) and the risk of CRC. Methods: The VEGF genotypes were determined using fresh colorectal tumor tissue from 477 patients with CRC who underwent surgical resection and peripheral blood lymphocytes from 413 healthy controls based on a polymerase chain reaction/denaturing high-performance liquid chromatography (PCR/DHPLC) assay. The incidence of genotypes and haplotypes of two VEGF polymorphisms was compared between the patients with CRC and the controls. Results: The distribution of genotypes and allele frequencies of the 936C > T polymorphism in the CRC group did not differ from those in the control group. However, compared with the combined GC and CC genotype, the GG genotype of +405G > C polymorphism was significantly associated with an increased risk of CRC [odds ratio (OR), 1.575; 95% confidence interval (CI), 1.178–2.104; P = 0.002]. In the haplotype analyses, haplotype +405G / 936C was also associated with a significantly increased risk of CRC (OR, 1.264; 95% CI, 1.043–1.531; P = 0.017), whereas haplotype +405C / 936C was associated with a decreased risk of CRC (OR, 0.818; 95% CI, 0.677–0.989; P = 0.038). None of the VEGF polymorphisms studied significantly influenced the clinical or pathologic features of CRC. Conclusions: These findings suggest that the VEGF +405G > C polymorphism may be associated with the risk of CRC in the Korean population. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- Y. Cho
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - Y. Chae
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - J. Kim
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - S. Shon
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - J. Moon
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - S. Jeon
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - J. Park
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - I. Lee
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - I. Lee
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - G. Choi
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - S. Jun
- Kyungpook National University Hospital, Daegu, Republic of Korea
| |
Collapse
|
42
|
Chae Y, Kim J, Sohn S, Cho Y, Moon J, Jeon S, Park J, Lee I, Choi G, Jun S. Vascular endothelial growth factor (VEGF) gene polymorphisms associated with prognosis for patients with colorectal cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.4125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4125 Background: Vascular endothelial growth factor (VEGF) or its family may be considered to play an important role in lymphangiogenesis and lymphatic tumor spread, thereby affecting prognosis of colorectal cancer. Accordingly, the present study analyzed VEGF gene polymorphisms and their impact on the prognosis for patients with colorectal cancer. Patients and Methods: Four hundred and sixty-five consecutive patients with surgically treated colorectal adenocarcinoma were enrolled in the present study. The genomic DNA was extracted from fresh colorectal tumor tissue and 3 VEGF (-2578C > A, -634G > C, and +936C > T) gene polymorphisms determined using a PCR/DHPLC (Polymerase chain reaction/Denaturing high-performance liquid chromatography) assay. Results: The median age of the patients was 64 years (range, 21–89), and 264 (56.7%) patients had colon cancer and 201 (48.2%) patients rectal cancer. Pathologic stages evaluable (n=464) after surgery were as follows: stage I (n=79, 17.0%), stage II (n=157, 33.8%), stage III (n=157, 33.8%), and stage IV (n=71, 15.3%). Multivariate survival analysis including stage, differentiation, and CEA level showed that survival for patients with the -634CC (overall survival [OS]: hazard ratio [HR]=0.175, P<0.001; progression-free survival [PFS]: HR=0.554, P=0.040) or GC genotype (OS: HR=0.158, P<0.001; PFS: HR=0.630, P=0.044) were better than for patients with the -634GG genotype, whereas the +936TT (OS: HR=65.959, P<0.001; PFS: HR=2.823, P=0.016) or CT genotype (OS: HR=16.116, P<0.001; PFS: HR=3.507, P<0.001) were associated with a worse survival compared to the CC genotype. In haplotype analysis, the -2578A/-634G/+936T haplotype exhibited a significantly worse survival when compared to the wild -2578C/-634G/+936C haplotype (OS: HR=4.670, P<0.001; PFS: HR=3.624, P<0.001). Conclusions: VEGF gene polymorphisms were found to be an independent prognostic marker for patients with colorectal cancer. Accordingly, the analysis of VEGF gene polymorphisms can help identify patient subgroups at high risk of a poor disease outcome. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- Y. Chae
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - J. Kim
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - S. Sohn
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - Y. Cho
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - J. Moon
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - S. Jeon
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - J. Park
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - I. Lee
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - G. Choi
- Kyungpook National University Hospital, Daegu, Republic of Korea
| | - S. Jun
- Kyungpook National University Hospital, Daegu, Republic of Korea
| |
Collapse
|
43
|
Joyce AT, Harrison DJ, Jun S, Feliu AL, Anthony M. Risk of renal failure associated with IV bisphosphonate use in patients with multiple myeloma. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.8104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8104 Background: IV Bisphosphonates including zoledronic acid (ZA) and pamidroniate are frequently used to delay time to skeletal related events in patients with multiple myeloma. The risk of renal toxicity with these agents is well known and regular monitoring of kidney function is required. Despite regular monitoring of creatinine, patients taking IV bisphosphonates may experience decreased renal functioning and renal failure. The purpose of this study was to determine the relative risk of renal failure in patients with multiple myeloma treated with ZA or pamidronate relative to patients whose lytic lesions remained untreated with medications. Methods: Commercially insured adults newly diagnosed with multiple myeloma 7/1/2002–6/2006 were identified using ICD-9 codes within the PHARMetrics Integrated Outcomes Database. Patients were stratified based on evidence of IV bisphosphonate use (treated) or no such evidence (untreated) following initial qualifying diagnosis. For treated patients, the date of first administration of an IV bisphosphonate was the patient's index date. Treated patients were matched to untreated patients based on use of radiation therapy or chemotherapy, year of cancer diagnosis, and health plan enrollment duration.The incidence rate (IR) for renal failure defined using ICD-9 codes was based on number of incident cases identified among the total person-years at risk and expressed as a rate per patient year. IRs and incidence rate ratios (IRR) (comparing the treated to untreated cohorts), with corresponding 95% confidence intervals are reported. Results: Treated (n=401) and untreated (n=431) patients were similar with respect to age (mean 56 years in both cohorts), but treated patients were more likely to be female (54% vs. 47%; p = 0.04) and less likely to have a history of anemia (48% vs. 51%; p=0.002). IV bisphosphonate use was associated with an 8.5% incidence of developing renal failure per patient year versus 4.9% in the untreated cohort (IRR 1.72; 95% CI 1.22–2.42). The risk was similar whether patients were treated with ZA or pamidronate. Conclusions: IV bisphosphonate use was associated with a significantly increased risk (72%) of developing renal failure in patients with multiple myeloma. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. T. Joyce
- PharMetrics, Inc., Watertown, MA; Amgen, Thousand Oaks, CA
| | - D. J. Harrison
- PharMetrics, Inc., Watertown, MA; Amgen, Thousand Oaks, CA
| | - S. Jun
- PharMetrics, Inc., Watertown, MA; Amgen, Thousand Oaks, CA
| | - A. L. Feliu
- PharMetrics, Inc., Watertown, MA; Amgen, Thousand Oaks, CA
| | - M. Anthony
- PharMetrics, Inc., Watertown, MA; Amgen, Thousand Oaks, CA
| |
Collapse
|
44
|
|
45
|
Lipton A, Alvarado C, De Boer R, Steger GG, Tonkin KS, Kinsey A, Fan M, Jun S. Randomized, active-controlled study of denosumab (AMG 162) in breast cancer patients with bone metastases not previously treated with intravenous (IV) bisphosphonates (BP). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.512] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
512 Background: Receptor activator of NF-κB ligand (RANKL) is a key mediator of osteoclast formation, function, and survival. Denosumab, a fully human monoclonal antibody, binds and inhibits RANKL, thus suppressing excess osteoclastic activity associated with bone metastases. We report interim efficacy and safety results of an ongoing, phase 2 study of denosumab in IV BP treatment-naïve women with advanced breast cancer and bone metastases (BM). Methods: Eligible patients (pts; age ≥ 18 yrs with breast cancer; confirmed BM; naive to IV BP therapy) were stratified by chemo- or hormonal therapy and randomized to 1 of 6 cohorts (5 denosumab [double blind]; 1 IV BP [open label]; see table ). The primary endpoint was the % change from baseline (BL) to week 13 in the resorption marker, urinary N-telopeptide (uNTx), corrected for creatinine. Also evaluated were % of pts with ≥ 65% decrease in uNTX from BL, time to a 65% reduction in uNTx, % of pts with ≥ 1 skeletal-related event (SRE), and safety. Results: In total, 255 pts (∼40/cohort) were enrolled. Mean age was 57 to 59 yrs (denosumab cohorts) vs 52 yrs (BP). Most pts had > 2 sites of BM (denosumab, 74%; BP, 81%); 51% and 49% received concurrent chemo- or hormonal therapy, respectively. As shown in the efficacy table , the 120 mg Q4W dose resulted in the greatest % decrease from BL in uNTx. At data cutoff, the % of all denosumab pts with ≥ 1 SRE was 9% (20/212) vs 16% (7/43) of BP pts. Commonly reported adverse events (AE) among all pts included nausea, vomiting, asthenia, diarrhea, and bone pain. Of 198 denosumab pts tested, none developed anti-denosumab antibodies. Conclusion: In this interim analysis, denosumab resulted in rapid and sustained suppression of bone turnover and was at least as effective as IV BP at reducing the risk of SREs, with a safety profile similar to that seen in advanced breast cancer pts receiving cancer treatment. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- A. Lipton
- Milton S. Hershey Medical Center, Hershey, PA; Hospital Juarez de Mexico, Mexico City, Mexico; Western Hospital, Footscray, Australia; Universitätsklinik für Innere Medizin, Wien, Austria; Cross Cancer Institute, Edmonton, AB, Canada; Amgen, Inc., Thousand Oaks, CA
| | - C. Alvarado
- Milton S. Hershey Medical Center, Hershey, PA; Hospital Juarez de Mexico, Mexico City, Mexico; Western Hospital, Footscray, Australia; Universitätsklinik für Innere Medizin, Wien, Austria; Cross Cancer Institute, Edmonton, AB, Canada; Amgen, Inc., Thousand Oaks, CA
| | - R. De Boer
- Milton S. Hershey Medical Center, Hershey, PA; Hospital Juarez de Mexico, Mexico City, Mexico; Western Hospital, Footscray, Australia; Universitätsklinik für Innere Medizin, Wien, Austria; Cross Cancer Institute, Edmonton, AB, Canada; Amgen, Inc., Thousand Oaks, CA
| | - G. G. Steger
- Milton S. Hershey Medical Center, Hershey, PA; Hospital Juarez de Mexico, Mexico City, Mexico; Western Hospital, Footscray, Australia; Universitätsklinik für Innere Medizin, Wien, Austria; Cross Cancer Institute, Edmonton, AB, Canada; Amgen, Inc., Thousand Oaks, CA
| | - K. S. Tonkin
- Milton S. Hershey Medical Center, Hershey, PA; Hospital Juarez de Mexico, Mexico City, Mexico; Western Hospital, Footscray, Australia; Universitätsklinik für Innere Medizin, Wien, Austria; Cross Cancer Institute, Edmonton, AB, Canada; Amgen, Inc., Thousand Oaks, CA
| | - A. Kinsey
- Milton S. Hershey Medical Center, Hershey, PA; Hospital Juarez de Mexico, Mexico City, Mexico; Western Hospital, Footscray, Australia; Universitätsklinik für Innere Medizin, Wien, Austria; Cross Cancer Institute, Edmonton, AB, Canada; Amgen, Inc., Thousand Oaks, CA
| | - M. Fan
- Milton S. Hershey Medical Center, Hershey, PA; Hospital Juarez de Mexico, Mexico City, Mexico; Western Hospital, Footscray, Australia; Universitätsklinik für Innere Medizin, Wien, Austria; Cross Cancer Institute, Edmonton, AB, Canada; Amgen, Inc., Thousand Oaks, CA
| | - S. Jun
- Milton S. Hershey Medical Center, Hershey, PA; Hospital Juarez de Mexico, Mexico City, Mexico; Western Hospital, Footscray, Australia; Universitätsklinik für Innere Medizin, Wien, Austria; Cross Cancer Institute, Edmonton, AB, Canada; Amgen, Inc., Thousand Oaks, CA
| |
Collapse
|
46
|
Suarez T, Fizazi K, Rahim Y, Wilson J, Fan M, Jun S, Lipton A. A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.8562] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8562 Background: Pts on established (≥ 8 weeks) IV BP who have elevated bone resorption markers, especially urinary N-telopeptide (uNTx), are at increased risk for skeletal related events (Coleman, J Clin Oncol 2005). Denosumab, a fully human monoclonal antibody, inhibits osteoclastic bone resorption by binding and neutralizing RANK ligand, a key mediator of osteoclast differentiation and function. Denosumab efficacy and safety were evaluated in a phase 2, randomized, open label, active-controlled study in advanced cancer pts with BM and elevated levels of uNTX despite established IV BP therapy. We report preliminary results from an interim analysis of 49 pts at week 13. Methods: Eligible pts (≥18 yrs old with solid tumor [except lung] or multiple myeloma [MM]; confirmed BM; screening uNTx > 50 nM BCE/mM creatinine [Cr]; on IV BP for ≥ 8 weeks before randomization) are stratified by baseline uNTx (50–100, >100) and tumor type. Pts are randomized to 1 of 3 arms: IV BP every 4 weeks (Q4W) or 180 mg denosumab given subcutaneously Q4W or Q12W. The primary endpoint is the proportion (%) of pts with uNTx < 50 nM BCE/mM Cr at week 13. Enrollment is ongoing (planned N = 135). Results: The mean (range) age of all pts in the analysis (33 denosumab; 16 BP) was 62.5 (39, 81) yrs; 96% had > 2 BM. The median time on prior IV BP (mostly zoledronic acid) was 5.1 months. Tumors included prostate (n = 24), breast (n = 20), other/MM (n = 5). The % of pts with uNTx < 50 nM BCE/mM Cr at week 13 was greater with denosumab (pooled arms) than IV BP: 76% (95% CI: 60.3, 91.2) vs 38% (95% CI: 18.5, 61.4; P = .015 Cochran-Mantel-Haenzel), respectively. No treatment-related serious adverse events (SAEs) were reported. Commonly reported AEs in the denosumab arms included nausea, peripheral edema, anemia, bone pain, and constipation. At data cutoff, 10 deaths (6/33 denosumab, 4/16 BP) had occurred on-study. Conclusions: These interim data suggest that denosumab normalizes uNTx more frequently than IV BP in pts with elevated uNTx despite 8 weeks of IV BP, across all tumor types. The AE profile of denosumab appeared similar to that of cancer pts undergoing treatment. [Table: see text]
Collapse
Affiliation(s)
- T. Suarez
- Hospital Regional ISSSTE, Merida, Mexico; Institut Gustave Roussy, Villejuif, France; Toronto East General Hospital, Toronto, ON, Canada; Amgen, Inc., Thousand Oaks, CA; Milton S. Hershey Medical Center, Hershey, PA
| | - K. Fizazi
- Hospital Regional ISSSTE, Merida, Mexico; Institut Gustave Roussy, Villejuif, France; Toronto East General Hospital, Toronto, ON, Canada; Amgen, Inc., Thousand Oaks, CA; Milton S. Hershey Medical Center, Hershey, PA
| | - Y. Rahim
- Hospital Regional ISSSTE, Merida, Mexico; Institut Gustave Roussy, Villejuif, France; Toronto East General Hospital, Toronto, ON, Canada; Amgen, Inc., Thousand Oaks, CA; Milton S. Hershey Medical Center, Hershey, PA
| | - J. Wilson
- Hospital Regional ISSSTE, Merida, Mexico; Institut Gustave Roussy, Villejuif, France; Toronto East General Hospital, Toronto, ON, Canada; Amgen, Inc., Thousand Oaks, CA; Milton S. Hershey Medical Center, Hershey, PA
| | - M. Fan
- Hospital Regional ISSSTE, Merida, Mexico; Institut Gustave Roussy, Villejuif, France; Toronto East General Hospital, Toronto, ON, Canada; Amgen, Inc., Thousand Oaks, CA; Milton S. Hershey Medical Center, Hershey, PA
| | - S. Jun
- Hospital Regional ISSSTE, Merida, Mexico; Institut Gustave Roussy, Villejuif, France; Toronto East General Hospital, Toronto, ON, Canada; Amgen, Inc., Thousand Oaks, CA; Milton S. Hershey Medical Center, Hershey, PA
| | - A. Lipton
- Hospital Regional ISSSTE, Merida, Mexico; Institut Gustave Roussy, Villejuif, France; Toronto East General Hospital, Toronto, ON, Canada; Amgen, Inc., Thousand Oaks, CA; Milton S. Hershey Medical Center, Hershey, PA
| |
Collapse
|
47
|
Acosta D, Affolder T, Akimoto T, Albrow MG, Ambrose D, Amerio S, Amidei D, Anastassov A, Anikeev K, Annovi A, Antos J, Aoki M, Apollinari G, Arisawa T, Arguin JF, Artikov A, Ashmanskas W, Attal A, Azfar F, Azzi-Bacchetta P, Bacchetta N, Bachacou H, Badgett W, Barbaro-Galtieri A, Barker GJ, Barnes VE, Barnett BA, Baroiant S, Barone M, Bauer G, Bedeschi F, Behari S, Belforte S, Bellettini G, Bellinger J, Benjamin D, Beretvas A, Bhatti A, Binkley M, Bisello D, Bishai M, Blair RE, Blocker C, Bloom K, Blumenfeld B, Bocci A, Bodek A, Bolla G, Bolshov A, Booth PSL, Bortoletto D, Boudreau J, Bourov S, Bromberg C, Brubaker E, Budagov J, Budd HS, Burkett K, Busetto G, Bussey P, Byrum KL, Cabrera S, Calafiura P, Campanelli M, Campbell M, Canepa A, Casarsa M, Carlsmith D, Carron S, Carosi R, Cavalli-Sforza M, Castro A, Catastini P, Cauz D, Cerri A, Cerri C, Cerrito L, Chapman J, Chen C, Chen YC, Chertok M, Chiarelli G, Chlachidze G, Chlebana F, Cho I, Cho K, Chokheli D, Chu ML, Chuang S, Chung JY, Chung WH, Chung YS, Ciobanu CI, Ciocci MA, Clark AG, Clark D, Coca M, Connolly A, Convery M, Conway J, Cooper B, Cordelli M, Cortiana G, Cranshaw J, Cuevas J, Culbertson R, Currat C, Cyr D, Dagenhart D, Da Ronco S, D'Auria S, de Barbaro P, De Cecco S, De Lentdecker G, Dell'agnello S, Dell'orso M, Demers S, Demortier L, Deninno M, De Pedis D, Derwent PF, Dionisi C, Dittmann JR, Doksus P, Dominguez A, Donati S, Donega M, Donini J, D'Onofrio M, Dorigo T, Drollinger V, Ebina K, Eddy N, Ely R, Erbacher R, Erdmann M, Errede D, Errede S, Eusebi R, Fang HC, Farrington S, Fedorko I, Feild RG, Feindt M, Fernandez JP, Ferretti C, Field RD, Fiori I, Flanagan G, Flaugher B, Flores-Castillo LR, Foland A, Forrester S, Foster GW, Franklin M, Freeman J, Frisch H, Fujii Y, Furic I, Gajjar A, Gallas A, Galyardt J, Gallinaro M, Garcia-Sciveres M, Garfinkel AF, Gay C, Gerberich H, Gerdes DW, Gerchtein E, Giagu S, Giannetti P, Gibson A, Gibson K, Ginsburg C, Giolo K, Giordani M, Giurgiu G, Glagolev V, Glenzinski D, Gold M, Goldschmidt N, Goldstein D, Goldstein J, Gomez G, Gomez-Ceballos G, Goncharov M, González O, Gorelov I, Goshaw AT, Gotra Y, Goulianos K, Gresele A, Griffiths M, Grosso-Pilcher C, Guenther M, Guimaraes da Costa J, Haber C, Hahn K, Hahn SR, Halkiadakis E, Handler R, Happacher F, Hara K, Hare M, Harr RF, Harris RM, Hartmann F, Hatakeyama K, Hauser J, Hays C, Hayward H, Heider E, Heinemann B, Heinrich J, Hennecke M, Herndon M, Hill C, Hirschbuehl D, Hocker A, Hoffman KD, Holloway A, Hou S, Houlden MA, Huffman BT, Huang Y, Hughes RE, Huston J, Ikado K, Incandela J, Introzzi G, Iori M, Ishizawa Y, Issever C, Ivanov A, Iwata Y, Iyutin B, James E, Jang D, Jarrell J, Jeans D, Jensen H, Jeon EJ, Jones M, Joo KK, Jun S, Junk T, Kamon T, Kang J, Karagoz Unel M, Karchin PE, Kartal S, Kato Y, Kemp Y, Kephart R, Kerzel U, Khotilovich V, Kilminster B, Kim DH, Kim HS, Kim JE, Kim MJ, Kim MS, Kim SB, Kim SH, Kim TH, Kim YK, King BT, Kirby M, Kirsch L, Klimenko S, Knuteson B, Ko BR, Kobayashi H, Koehn P, Kong DJ, Kondo K, Konigsberg J, Kordas K, Korn A, Korytov A, Kotelnikov K, Kotwal AV, Kovalev A, Kraus J, Kravchenko I, Kreymer A, Kroll J, Kruse M, Krutelyov V, Kuhlmann SE, Kuznetsova N, Laasanen AT, Lai S, Lami S, Lammel S, Lancaster J, Lancaster M, Lander R, Lannon K, Lath A, Latino G, Lauhakangas R, Lazzizzera I, Le Y, Lecci C, Lecompte T, Lee J, Lee J, Lee SW, Leonardo N, Leone S, Lewis JD, Li K, Lin C, Lin CS, Lindgren M, Liss TM, Litvintsev DO, Liu T, Liu Y, Lockyer NS, Loginov A, Loreti M, Loverre P, Lu RS, Lucchesi D, Lujan P, Lukens P, Lyons L, Lys J, Lysak R, Macqueen D, Madrak R, Maeshima K, Maksimovic P, Malferrari L, Manca G, Marginean R, Martin M, Martin A, Martin V, Martínez M, Maruyama T, Matsunaga H, Mattson M, Mazzanti P, McFarland KS, McGivern D, McIntyre PM, McNamara P, Ncnulty R, Menzemer S, Menzione A, Merkel P, Mesropian C, Messina A, Miao T, Miladinovic N, Miller L, Miller R, Miller JS, Miquel R, Miscetti S, Mitselmakher G, Miyamoto A, Miyazaki Y, Moggi N, Mohr B, Moore R, Morello M, Mukherjee A, Mulhearn M, Muller T, Mumford R, Munar A, Murat P, Nachtman J, Nahn S, Nakamura I, Nakano I, Napier A, Napora R, Naumov D, Necula V, Niell F, Nielsen J, Nelson C, Nelson T, Neu C, Neubauer MS, Newman-Holmes C, Nicollerat AS, Nigmanov T, Nodulman L, Norniella O, Oesterberg K, Ogawa T, Oh SH, Oh YD, Ohsugi T, Okusawa T, Oldeman R, Orava R, Orejudos W, Pagliarone C, Palmonari F, Paoletti R, Papadimitriou V, Pashapour S, Patrick J, Pauletta G, Paulini M, Pauly T, Paus C, Pellett D, Penzo A, Phillips TJ, Piacentino G, Piedra J, Pitts KT, Plager C, Pompos A, Pondrom L, Pope G, Poukhov O, Prakoshyn F, Pratt T, Pronko A, Proudfoot J, Ptohos F, Punzi G, Rademacker J, Rakitine A, Rappoccio S, Ratnikov F, Ray H, Reichold A, Reisert B, Rekovic V, Renton P, Rescigno M, Rimondi F, Rinnert K, Ristori L, Robertson WJ, Robson A, Rodrigo T, Rolli S, Rosenson L, Roser R, Rossin R, Rott C, Russ J, Ruiz A, Ryan D, Saarikko H, Safonov A, St Denis R, Sakumoto WK, Salamanna G, Saltzberg D, Sanchez C, Sansoni A, Santi L, Sarkar S, Sato K, Savard P, Savoy-Navarro A, Schemitz P, Schlabach P, Schmidt EE, Schmidt MP, Schmitt M, Scodellaro L, Scribano A, Scuri F, Sedov A, Seidel S, Seiya Y, Semeria F, Sexton-Kennedy L, Sfiligoi I, Shapiro MD, Shears T, Shepard PF, Shimojima M, Shochet M, Shon Y, Shreyber I, Sidoti A, Siegrist J, Siket M, Sill A, Sinervo P, Sisakyan A, Skiba A, Slaughter AJ, Sliwa K, Smirnov D, Smith JR, Snider FD, Snihur R, Somalwar SV, Spalding J, Spezziga M, Spiegel L, Spinella F, Spiropulu M, Squillacioti P, Stadie H, Stefanini A, Stelzer B, Stelzer-Chilton O, Strologas J, Stuart D, Sukhanov A, Sumorok K, Sun H, Suzuki T, Taffard A, Tafirout R, Takach SF, Takano H, Takashima R, Takeuchi Y, Takikawa K, Tanaka M, Tanaka R, Tanimoto N, Tapprogge S, Tecchio M, Teng PK, Terashi K, Tesarek RJ, Tether S, Thom J, Thompson AS, Thomson E, Tipton P, Tiwari V, Tkaczyk S, Toback D, Tollefson K, Tomura T, Tonelli D, Tönnesmann M, Torre S, Torretta D, Trischuk W, Tseng J, Tsuchiya R, Tsuno S, Tsybychev D, Turini N, Turner M, Ukegawa F, Unverhau T, Uozumi S, Usynin D, Vacavant L, Vaiciulis A, Varganov A, Vataga E, Vejcik S, Velev G, Veramendi G, Vickey T, Vidal R, Vila I, Vilar R, Volobouev I, von der Mey M, Wagner P, Wagner RG, Wagner RL, Wagner W, Wallny R, Walter T, Yamashita T, Yamamoto K, Wan Z, Wang MJ, Wang SM, Warburton A, Ward B, Waschke S, Waters D, Watts T, Weber M, Wester WC, Whitehouse B, Wicklund AB, Wicklund E, Williams HH, Wilson P, Winer BL, Wittich P, Wolbers S, Wolter M, Worcester M, Worm S, Wright T, Wu X, Würthwein F, Wyatt A, Yagil A, Yang UK, Yao W, Yeh GP, Yi K, Yoh J, Yoon P, Yorita K, Yoshida T, Yu I, Yu S, Yu Z, Yun JC, Zanello L, Zanetti A, Zaw I, Zetti F, Zhou J, Zsenei A, Zucchelli S. Measurement of partial widths and search for direct CP violation in D0 meson decays to K-K+ and pi-pi+. Phys Rev Lett 2005; 94:122001. [PMID: 15903906 DOI: 10.1103/physrevlett.94.122001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/06/2004] [Indexed: 05/02/2023]
Abstract
We present a measurement of relative partial widths and decay rate CP asymmetries in K-K+ and pi(-)pi(+) decays of D0 mesons produced in pp collisions at sqrt[s]=1.96 TeV. We use a sample of 2x10(5) D(*+)-->D0pi(+) (and charge conjugate) decays with the D0 decaying to K-pi(+), K-K+, and pi(-)pi(+), corresponding to 123 pb(-1) of data collected by the Collider Detector at Fermilab II experiment at the Fermilab Tevatron collider. No significant direct CP violation is observed. We measure Gamma(D0-->K-K+)/Gamma(D0-->K-pi(+))=0.0992+/-0.0011+/-0.0012, Gamma(D0-->pi(-)pi(+))/Gamma(D0-->K-pi(+))=0.035 94+/-0.000 54+/-0.000 40, A(CP)(K-K+)=(2.0+/-1.2+/-0.6)%, and A(CP)(pi(-)pi(+))=(1.0+/-1.3+/-0.6)%, where, in all cases, the first uncertainty is statistical and the second is systematic.
Collapse
Affiliation(s)
- D Acosta
- University of Florida, Gainesville, Florida 32611, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Acosta D, Adelman J, Affolder T, Akimoto T, Albrow MG, Ambrose D, Amerio S, Amidei D, Anastassov A, Anikeev K, Annovi A, Antos J, Aoki M, Apollinari G, Arisawa T, Arguin JF, Artikov A, Ashmanskas W, Attal A, Azfar F, Azzi-Bacchetta P, Bacchetta N, Bachacou H, Badgett W, Barbaro-Galtieri A, Barker GJ, Barnes VE, Barnett BA, Baroiant S, Barone M, Bauer G, Bedeschi F, Behari S, Belforte S, Bellettini G, Bellinger J, Ben-Haim E, Benjamin D, Beretvas A, Bhatti A, Binkley M, Bisello D, Bishai M, Blair RE, Blocker C, Bloom K, Blumenfeld B, Bocci A, Bodek A, Bolla G, Bolshov A, Booth PSL, Bortoletto D, Boudreau J, Bourov S, Bromberg C, Brubaker E, Budagov J, Budd HS, Burkett K, Busetto G, Bussey P, Byrum KL, Cabrera S, Campanelli M, Campbell M, Canepa A, Casarsa M, Carlsmith D, Carron S, Carosi R, Cavalli-Sforza M, Castro A, Catastini P, Cauz D, Cerri A, Cerri C, Cerrito L, Chapman J, Chen C, Chen YC, Chertok M, Chiarelli G, Chlachidze G, Chlebana F, Cho I, Cho K, Chokheli D, Chu ML, Chuang S, Chung JY, Chung WH, Chung YS, Ciobanu CI, Ciocci MA, Clark AG, Clark D, Coca M, Connolly A, Convery M, Conway J, Cooper B, Cordelli M, Cortiana G, Cranshaw J, Cuevas J, Culbertson R, Currat C, Cyr D, Dagenhart D, Da Ronco S, D'Auria S, de Barbaro P, De Cecco S, De Lentdecker G, Dell'Agnello S, Dell'Orso M, Demers S, Demortier L, Deninno M, De Pedis D, Derwent PF, Dionisi C, Dittmann JR, Doksus P, Dominguez A, Donati S, Donega M, Donini J, D'Onofrio M, Dorigo T, Drollinger V, Ebina K, Eddy N, Ely R, Erbacher R, Erdmann M, Errede D, Errede S, Eusebi R, Fang HC, Farrington S, Fedorko I, Feild RG, Feindt M, Fernandez JP, Ferretti C, Field RD, Fiori I, Flanagan G, Flaugher B, Flores-Castillo LR, Foland A, Forrester S, Foster GW, Franklin M, Freeman JC, Frisch H, Fujii Y, Furic I, Gajjar A, Gallas A, Galyardt J, Gallinaro M, Garfinkel AF, Gay C, Gerberich H, Gerdes DW, Gerchtein E, Giagu S, Giannetti P, Gibson A, Gibson K, Ginsburg C, Giolo K, Giordani M, Giurgiu G, Glagolev V, Glenzinski D, Gold M, Goldschmidt N, Goldstein D, Goldstein J, Gomez G, Gomez-Ceballos G, Goncharov M, González O, Gorelov I, Goshaw AT, Gotra Y, Goulianos K, Gresele A, Griffiths M, Grosso-Pilcher C, Grundler U, Guenther M, da Costa JG, Haber C, Hahn K, Hahn SR, Halkiadakis E, Hamilton A, Han BY, Handler R, Happacher F, Hara K, Hare M, Harr RF, Harris RM, Hartmann F, Hatakeyama K, Hauser J, Hays C, Hayward H, Heider E, Heinemann B, Heinrich J, Hennecke M, Herndon M, Hill C, Hirschbuehl D, Hocker A, Hoffman KD, Holloway A, Hou S, Houlden MA, Huffman BT, Huang Y, Hughes RE, Huston J, Ikado K, Incandela J, Introzzi G, Iori M, Ishizawa Y, Issever C, Ivanov A, Iwata Y, Iyutin B, James E, Jang D, Jarrell J, Jeans D, Jensen H, Jeon EJ, Jones M, Joo KK, Jun S, Junk T, Kamon T, Kang J, Karagoz Unel M, Karchin PE, Kartal S, Kato Y, Kemp Y, Kephart R, Kerzel U, Khotilovich V, Kilminster B, Kim DH, Kim HS, Kim JE, Kim MJ, Kim MS, Kim SB, Kim SH, Kim TH, Kim YK, King BT, Kirby M, Kirsch L, Klimenko S, Knuteson B, Ko BR, Kobayashi H, Koehn P, Kong DJ, Kondo K, Konigsberg J, Kordas K, Korn A, Korytov A, Kotelnikov K, Kotwal AV, Kovalev A, Kraus J, Kravchenko I, Kreymer A, Kroll J, Kruse M, Krutelyov V, Kuhlmann SE, Kuznetsova N, Laasanen AT, Lai S, Lami S, Lammel S, Lancaster J, Lancaster M, Lander R, Lannon K, Lath A, Latino G, Lauhakangas R, Lazzizzera I, Le Y, Lecci C, Lecompte T, Lee J, Lee J, Lee SW, Lefevre R, Leonardo N, Leone S, Lewis JD, Li K, Lin C, Lin CS, Lindgren M, Liss TM, Litvintsev DO, Liu T, Liu Y, Lockyer NS, Loginov A, Loreti M, Loverre P, Lu RS, Lucchesi D, Lujan P, Lukens P, Lungu G, Lyons L, Lys J, Lysak R, Macqueen D, Madrak R, Maeshima K, Maksimovic P, Malferrari L, Manca G, Marginean R, Martin M, Martin A, Martin V, Martínez M, Maruyama T, Matsunaga H, Mattson M, Mazzanti P, McFarland KS, McGivern D, McIntyre PM, McNamara P, NcNulty R, Menzemer S, Menzione A, Merkel P, Mesropian C, Messina A, Miao T, Miladinovic N, Miller L, Miller R, Miller JS, Miquel R, Miscetti S, Mitselmakher G, Miyamoto A, Miyazaki Y, Moggi N, Mohr B, Moore R, Morello M, Mukherjee A, Mulhearn M, Muller T, Mumford R, Munar A, Murat P, Nachtman J, Nahn S, Nakamura I, Nakano I, Napier A, Napora R, Naumov D, Necula V, Niell F, Nielsen J, Nelson C, Nelson T, Neu C, Neubauer MS, Newman-Holmes C, Nicollerat AS, Nigmanov T, Nodulman L, Norniella O, Oesterberg K, Ogawa T, Oh SH, Oh YD, Ohsugi T, Okusawa T, Oldeman R, Orava R, Orejudos W, Pagliarone C, Palencia E, Palmonari F, Paoletti R, Papadimitriou V, Pashapour S, Patrick J, Pauletta G, Paulini M, Pauly T, Paus C, Pellett D, Penzo A, Phillips TJ, Piacentino G, Piedra J, Pitts KT, Plager C, Pompos A, Pondrom L, Pope G, Poukhov O, Prakoshyn F, Pratt T, Pronko A, Proudfoot J, Ptohos F, Punzi G, Rademacker J, Rakitine A, Rappoccio S, Ratnikov F, Ray H, Reichold A, Reisert B, Rekovic V, Renton P, Rescigno M, Rimondi F, Rinnert K, Ristori L, Robertson WJ, Robson A, Rodrigo T, Rolli S, Rosenson L, Roser R, Rossin R, Rott C, Russ J, Ruiz A, Ryan D, Saarikko H, Sabik S, Safonov A, St Denis R, Sakumoto WK, Salamanna G, Saltzberg D, Sanchez C, Sansoni A, Santi L, Sarkar S, Sato K, Savard P, Savoy-Navarro A, Schlabach P, Schmidt EE, Schmidt MP, Schmitt M, Scodellaro L, Scribano A, Scuri F, Sedov A, Seidel S, Seiya Y, Semeria F, Sexton-Kennedy L, Sfiligoi I, Shapiro MD, Shears T, Shepard PF, Shimojima M, Shochet M, Shon Y, Shreyber I, Sidoti A, Siegrist J, Siket M, Sill A, Sinervo P, Sisakyan A, Skiba A, Slaughter AJ, Sliwa K, Smirnov D, Smith JR, Snider FD, Snihur R, Somalwar SV, Spalding J, Spezziga M, Spiegel L, Spinella F, Spiropulu M, Squillacioti P, Stadie H, Stefanini A, Stelzer B, Stelzer-Chilton O, Strologas J, Stuart D, Sukhanov A, Sumorok K, Sun H, Suzuki T, Taffard A, Tafirout R, Takach SF, Takano H, Takashima R, Takeuchi Y, Takikawa K, Tanaka M, Tanaka R, Tanimoto N, Tapprogge S, Tecchio M, Teng PK, Terashi K, Tesarek RJ, Tether S, Thom J, Thompson AS, Thomson E, Tipton P, Tiwari V, Tkaczyk S, Toback D, Tollefson K, Tomura T, Tonelli D, Tönnesmann M, Torre S, Torretta D, Tourneur S, Trischuk W, Tseng J, Tsuchiya R, Tsuno S, Tsybychev D, Turini N, Turner M, Ukegawa F, Unverhau T, Uozumi S, Usynin D, Vacavant L, Vaiciulis A, Varganov A, Vataga E, Vejcik S, Velev G, Veszpremi V, Veramendi G, Vickey T, Vidal R, Vila I, Vilar R, Vollrath I, Volobouev I, von der Mey M, Wagner P, Wagner RG, Wagner RL, Wagner W, Wallny R, Walter T, Yamashita T, Yamamoto K, Wan Z, Wang MJ, Wang SM, Warburton A, Ward B, Waschke S, Waters D, Watts T, Weber M, Wester WC, Whitehouse B, Wicklund AB, Wicklund E, Williams HH, Wilson P, Winer BL, Wittich P, Wolbers S, Wolter M, Worcester M, Worm S, Wright T, Wu X, Würthwein F, Wyatt A, Yagil A, Yang UK, Yao W, Yeh GP, Yi K, Yoh J, Yoon P, Yorita K, Yoshida T, Yu I, Yu S, Yu Z, Yun JC, Zanello L, Zanetti A, Zaw I, Zetti F, Zhou J, Zsenei A, Zucchelli S. Search for excited and exotic electrons in the egamma decay channel in pp collisions at sqrt[s] = 1.96 TeV. Phys Rev Lett 2005; 94:101802. [PMID: 15783472 DOI: 10.1103/physrevlett.94.101802] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/06/2004] [Indexed: 05/24/2023]
Abstract
We present a search for excited and exotic electrons (e(*)) decaying to an electron and a photon, both with high transverse momentum. We use 202 pb(-1) of data collected in pp collisions at sqrt[s] = 1.96 TeV with the Collider Detector at Fermilab II detector. No signal above standard model expectation is seen for associated ee(*) production. We discuss the e(*) sensitivity in the parameter space of the excited electron mass M(e(*)) and the compositeness energy scale Lambda. In the contact interaction model, we exclude 132 GeV/c(2)<M(e(*))<879 GeV/c(2) for Lambda = M(e(*)) at 95% confidence level (C.L.). In the gauge-mediated model, we exclude 126 GeV/c(2) < M(e(*)) < 430 GeV/c(2) at 95% C.L. for the phenomenological coupling f/Lambda approximately 10(-2) GeV-1.
Collapse
Affiliation(s)
- D Acosta
- University of Florida, Gainesville, Florida 32611, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Acosta D, Affolder T, Akimoto T, Albrow MG, Ambrose D, Amerio S, Amidei D, Anastassov A, Anikeev K, Annovi A, Antos J, Aoki M, Apollinari G, Arisawa T, Arguin JF, Artikov A, Ashmanskas W, Attal A, Azfar F, Azzi-Bacchetta P, Bacchetta N, Bachacou H, Badgett W, Barbaro-Galtieri A, Barker GJ, Barnes VE, Barnett BA, Baroiant S, Barone M, Bauer G, Bedeschi F, Behari S, Belforte S, Bellettini G, Bellinger J, Benjamin D, Beretvas A, Bhatti A, Binkley M, Bisello D, Bishai M, Blair RE, Blocker C, Bloom K, Blumenfeld B, Bocci A, Bodek A, Bolla G, Bolshov A, Booth PSL, Bortoletto D, Boudreau J, Bourov S, Bromberg C, Brubaker E, Budagov J, Budd HS, Burkett K, Busetto G, Bussey P, Byrum KL, Cabrera S, Calafiura P, Campanelli M, Campbell M, Canepa A, Casarsa M, Carlsmith D, Carron S, Carosi R, Cavalli-Sforza M, Castro A, Catastini P, Cauz D, Cerri A, Cerri C, Cerrito L, Chapman J, Chen C, Chen YC, Chertok M, Chiarelli G, Chlachidze G, Chlebana F, Cho I, Cho K, Chokheli D, Chu ML, Chuang S, Chung JY, Chung WH, Chung YS, Ciobanu CI, Ciocci MA, Clark AG, Clark D, Coca M, Connolly A, Convery M, Conway J, Cooper B, Cordelli M, Cortiana G, Cranshaw J, Cuevas J, Culbertson R, Currat C, Cyr D, Dagenhart D, Da Ronco S, D'Auria S, de Barbaro P, De Cecco S, De Lentdecker G, Dell'Agnello S, Dell'Orso M, Demers S, Demortier L, Deninno M, De Pedis D, Derwent PF, Dionisi C, Dittmann JR, Doksus P, Dominguez A, Donati S, Donega M, Donini J, D'Onofrio M, Dorigo T, Drollinger V, Ebina K, Eddy N, Ely R, Erbacher R, Erdmann M, Errede D, Errede S, Eusebi R, Fang HC, Farrington S, Fedorko I, Feild RG, Feindt M, Fernandez JP, Ferretti C, Field RD, Fiori I, Flanagan G, Flaugher B, Flores-Castillo LR, Foland A, Forrester S, Foster GW, Franklin M, Freeman J, Frisch H, Fujii Y, Furic I, Gajjar A, Gallas A, Galyardt J, Gallinaro M, Garcia-Sciveres M, Garfinkel AF, Gay C, Gerberich H, Gerdes DW, Gerchtein E, Giagu S, Giannetti P, Gibson A, Gibson K, Ginsburg C, Giolo K, Giordani M, Giurgiu G, Glagolev V, Glenzinski D, Gold M, Goldschmidt N, Goldstein D, Goldstein J, Gomez G, Gomez-Ceballos G, Goncharov M, González O, Gorelov I, Goshaw AT, Gotra Y, Goulianos K, Gresele A, Grosso-Pilcher C, Guenther M, Guimaraes da Costa J, Haber C, Hahn K, Hahn SR, Halkiadakis E, Handler R, Happacher F, Hara K, Hare M, Harr RF, Harris RM, Hartmann F, Hatakeyama K, Hauser J, Hays C, Hayward H, Heider E, Heinemann B, Heinrich J, Hennecke M, Herndon M, Hill C, Hirschbuehl D, Hocker A, Hoffman KD, Holloway A, Hou S, Houlden MA, Huffman BT, Huang Y, Hughes RE, Huston J, Ikado K, Incandela J, Introzzi G, Iori M, Ishizawa Y, Issever C, Ivanov A, Iwata Y, Iyutin B, James E, Jang D, Jarrell J, Jeans D, Jensen H, Jeon EJ, Jones M, Joo KK, Jun S, Junk T, Kamon T, Kang J, Karagoz Unel M, Karchin PE, Kartal S, Kato Y, Kemp Y, Kephart R, Kerzel U, Khotilovich V, Kilminster B, Kim DH, Kim HS, Kim JE, Kim MJ, Kim MS, Kim SB, Kim SH, Kim TH, Kim YK, King BT, Kirby M, Kirsch L, Klimenko S, Knuteson B, Ko BR, Kobayashi H, Koehn P, Kong DJ, Kondo K, Konigsberg J, Kordas K, Korn A, Korytov A, Kotelnikov K, Kotwal AV, Kovalev A, Kraus J, Kravchenko I, Kreymer A, Kroll J, Kruse M, Krutelyov V, Kuhlmann SE, Kuznetsova N, Laasanen AT, Lai S, Lami S, Lammel S, Lancaster J, Lancaster M, Lander R, Lannon K, Lath A, Latino G, Lauhakangas R, Lazzizzera I, Le Y, Lecci C, Lecompte T, Lee J, Lee J, Lee SW, Leonardo N, Leone S, Lewis JD, Li K, Lin C, Lin CS, Lindgren M, Liss TM, Litvintsev DO, Liu T, Liu Y, Lockyer NS, Loginov A, Loreti M, Loverre P, Lu RS, Lucchesi D, Lujan P, Lukens P, Lyons L, Lys J, Lysak R, Macqueen D, Madrak R, Maeshima K, Maksimovic P, Malferrari L, Manca G, Marginean R, Martin M, Martin A, Martin V, Martínez M, Maruyama T, Matsunaga H, Mattson M, Mazzanti P, McFarland KS, McGivern D, McIntyre PM, McNamara P, Ncnulty R, Menzemer S, Menzione A, Merkel P, Mesropian C, Messina A, Miao T, Miladinovic N, Miller L, Miller R, Miller JS, Miquel R, Miscetti S, Mitselmakher G, Miyamoto A, Miyazaki Y, Moggi N, Mohr B, Moore R, Morello M, Moulik T, Movilla Fernandez PA, Mukherjee A, Mulhearn M, Muller T, Mumford R, Munar A, Murat P, Nachtman J, Nahn S, Nakamura I, Nakano I, Napier A, Napora R, Naumov D, Necula V, Niell F, Nielsen J, Nelson C, Nelson T, Neu C, Neubauer MS, Newman-Holmes C, Nicollerat AS, Nigmanov T, Nodulman L, Norniella O, Oesterberg K, Ogawa T, Oh SH, Oh YD, Ohsugi T, Okusawa T, Oldeman R, Orava R, Orejudos W, Pagliarone C, Palmonari F, Paoletti R, Papadimitriou V, Pashapour S, Patrick J, Pauletta G, Paulini M, Pauly T, Paus C, Pellett D, Penzo A, Phillips TJ, Piacentino G, Piedra J, Pitts KT, Plager C, Pompos A, Pondrom L, Pope G, Poukhov O, Prakoshyn F, Pratt T, Pronko A, Proudfoot J, Ptohos F, Punzi G, Rademacker J, Rakitine A, Rappoccio S, Ratnikov F, Ray H, Reichold A, Reisert B, Rekovic V, Renton P, Rescigno M, Rimondi F, Rinnert K, Ristori L, Robertson WJ, Robson A, Rodrigo T, Rolli S, Rosenson L, Roser R, Rossin R, Rott C, Russ J, Ruiz A, Ryan D, Saarikko H, Safonov A, St Denis R, Sakumoto WK, Salamanna G, Saltzberg D, Sanchez C, Sansoni A, Santi L, Sarkar S, Sato K, Savard P, Savoy-Navarro A, Schemitz P, Schlabach P, Schmidt EE, Schmidt MP, Schmitt M, Scodellaro L, Scribano A, Scuri F, Sedov A, Seidel S, Seiya Y, Semeria F, Sexton-Kennedy L, Sfiligoi I, Shapiro MD, Shears T, Shepard PF, Shimojima M, Shochet M, Shon Y, Shreyber I, Sidoti A, Siegrist J, Siket M, Sill A, Sinervo P, Sisakyan A, Skiba A, Slaughter AJ, Sliwa K, Smirnov D, Smith JR, Snider FD, Snihur R, Somalwar SV, Spalding J, Spezziga M, Spiegel L, Spinella F, Spiropulu M, Squillacioti P, Stadie H, Stefanini A, Stelzer B, Stelzer-Chilton O, Strologas J, Stuart D, Sukhanov A, Sumorok K, Sun H, Suzuki T, Taffard A, Tafirout R, Takach SF, Takano H, Takashima R, Takeuchi Y, Takikawa K, Tanaka M, Tanaka R, Tanimoto N, Tapprogge S, Tecchio M, Teng PK, Terashi K, Tesarek RJ, Tether S, Thom J, Thompson AS, Thomson E, Tipton P, Tiwari V, Tkaczyk S, Toback D, Tollefson K, Tomura T, Tonelli D, Tönnesmann M, Torre S, Torretta D, Trischuk W, Tseng J, Tsuchiya R, Tsuno S, Tsybychev D, Turini N, Turner M, Ukegawa F, Unverhau T, Uozumi S, Usynin D, Vacavant L, Vaiciulis A, Varganov A, Vataga E, Vejcik S, Velev G, Veramendi G, Vickey T, Vidal R, Vila I, Vilar R, Volobouev I, von der Mey M, Wagner RG, Wagner RL, Wagner W, Wallny R, Walter T, Yamashita T, Yamamoto K, Wan Z, Wang MJ, Wang SM, Warburton A, Ward B, Waschke S, Waters D, Watts T, Weber M, Wester WC, Whitehouse B, Wicklund AB, Wicklund E, Williams HH, Wilson P, Winer BL, Wittich P, Wolbers S, Wolter M, Worcester M, Worm S, Wright T, Wu X, Würthwein F, Wyatt A, Yagil A, Yang UK, Yao W, Yeh GP, Yi K, Yoh J, Yoon P, Yorita K, Yoshida T, Yu I, Yu S, Yu Z, Yun JC, Zanello L, Zanetti A, Zaw I, Zetti F, Zhou J, Zsenei A, Zucchelli S. First measurements of inclusive W and Z cross sections from run II of the fermilab tevatron collider. Phys Rev Lett 2005; 94:091803. [PMID: 15783955 DOI: 10.1103/physrevlett.94.091803] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/28/2004] [Indexed: 05/24/2023]
Abstract
We report the first measurements of inclusive W and Z cross sections times leptonic branching ratios for pp collisions at square root[s]=1.96 TeV, based on their decays to electrons and muons. The data correspond to an integrated luminosity of 72 pb(-1) recorded with the CDF detector at the Fermilab Tevatron. We test e-mu universality in W decays, and we measure the ratio of leptonic W and Z rates from which the leptonic branching fraction B(W-->lnu) can be extracted as well as an indirect value for the total width of the W and the Cabibbo-Kobayashi-Maskawa matrix element, |V(cs)|.
Collapse
Affiliation(s)
- D Acosta
- University of Florida, Gainesville, Florida 32611, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Abstract
Amphiphilic peptides suspended in aqueous solution display a rich set of aggregation behavior. Molecular-level studies of relatively simple amphiphilic molecules under controlled conditions are an essential step toward a better understanding of self-assembly phenomena of naturally occurring peptides/proteins. Here, we study the influence of molecular architecture and interactions on the self-assembly of model peptides (EAK16s), using both experimental and theoretical approaches. Three different types of EAK16 were studied: EAK16-I, -II, and -IV, which have the same amino acid composition but different amino acid sequences. Atomic force microscopy confirms that EAK16-I and -II form fibrillar assemblies, whereas EAK16-IV forms globular structures. The Fourier transform infrared spectrum of EAK16-IV indicates the possible formation of a beta-turn structure, which is not found in EAK16-I and -II. Our theoretical and numerical studies suggest the underlying mechanism behind these observations. We show that the hairpin structure is energetically stable for EAK16-IV, whereas the chain entropy of EAK16-I and -II favors relatively stretched conformations. Our combined experimental and theoretical approaches provide a clear picture of the interplay between single-chain properties, as determined by peptide sequences (or charge distributions), and the emerging structure at the nano (or more coarse-grained) level.
Collapse
Affiliation(s)
- S Jun
- Department of Physics, Simon Fraser University, Burnaby, British Columbia V5A 1S6, Canada
| | | | | | | | | | | |
Collapse
|